Login to Your Account


RESEARCH 'WAVE CRESTING,' SAYS CEO

Hemispherx Biopharma Inc. CEO Thomas Equels told BioWorld Today that the approval in the Argentine Republic of rintatolimod for severe ME/CFS is “the opening of a door” to the rest of the world, which is waking up to the reality of the disease.

more »


Analysis

Although Infinity Pharmaceuticals Inc. CEO Adelene Perkins said her firm's "going-in assumption is that we will be successful" in selling rights to phosphoinositide 3-kinase (PI3K) inhibitor duvelisib, Abbvie Inc.'s decision to pull out of their partnership undoubtedly threw cold water on the class.

read more »